|
|
 |
|
Viewing report
|
|
|
|
Daiichi Sankyo: PharmaVitae Profile 2005
Datamonitor, April 2006, Pages: 135
This analysis examines the current position and future outlook for Daiichi Sankyo in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to order your copy:
- Benchmark Daiichi Sankyos performance against key rivals in the ethical pharmaceutical sector
- Learn how the integration of Daiichi Sankyo compares with the mergers of Yamanouchi and Fujisawa (Astellas) and Dainippon and Sumitomo
- Evaluate Benicars chances of achieving blockbuster status and offsetting, fellow cardiovascular drug, Mevalotins continued decline in sales
Customers who bought this item also bought
Daiichi Sankyo: Pipeline, Products, Performance and Potential
Daiichi Sankyo IMS Company Profiles
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review
PharmaVitae 2004: Daiichi Pharmaceuticals Global and US Analysis
Daiichi Sankyo: PharmaVitae Profile
Daiichi Sankyo Pharma Partnering Guide 2008
PharmaVitae 2004: Daiichi Pharmaceuticals Global Analysis
PharmaVitae 2003: Sankyo
Daiichi Sankyo Co., Ltd: PharmaVitae Model
Daiichi Sankyo Company Limited
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Daiichi Sankyo, Ltd. - SWOT Analysis - SWOT Analysis
|
|
|
|
